Abstract
Recombinant immunotoxins are new agents being developed for cancer therapy. They are composed of Fv fragments of antibodies that bind to cancer cells fused to a truncated form of a very potent bacterial toxin. The antibody moiety directs the toxin to cancer cells, which are killed, while normal cells are not recognized and thus survive. The excellent preclinical results in vitro and in vivo have led to the initiation of several clinical trials.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Humans
-
Immunoglobulin Variable Region / genetics*
-
Immunotoxins / genetics
-
Immunotoxins / therapeutic use*
-
Leukemia / therapy
-
Lymphoma / therapy
-
Neoplasms / diagnosis*
-
Neoplasms / therapy*
-
Prodrugs / administration & dosage
-
Radioimmunotherapy
-
Recombinant Fusion Proteins / genetics
-
Recombinant Fusion Proteins / metabolism
-
Recombinant Fusion Proteins / pharmacology
Substances
-
Immunoglobulin Variable Region
-
Immunotoxins
-
Prodrugs
-
Recombinant Fusion Proteins